ESCONDIDO, Calif.–(BUSINESS WIRE)–Enthorin Therapeutics, LLC today announced that it has entered into an option-to-license agreement with Rumi Therapeutics for ENT-7340, Enthorin’s IND-enabled phosphodiesterase 2A (PDE2A) inhibitor being developed for Fragile X syndrome (FXS) and other intellectual and developmental disabilities. Under the agreement, Rumi Therapeutics will assume responsibility for development of ENT-7340, which will be advanced by Rumi under the development name RTX-7340. En